Assessing HER-2 status in fresh frozen and archival cytological samples obtained by fine needle aspiration cytology

Cytopathology

Volumn 15, Issue 6, 2004, Pages 311-314

  Tomás, Ana Raquel ^a   Praca M J ^a   Fonseca, R ^a   Andre S ^a   Mendonca E ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

Author keywords

Breast cancer; Fine needle aspiration cytology; FISH; HER 2; Pre treatment protocols

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; ASPIRATION BIOPSY; ASPIRATION CYTOLOGY; BREAST BIOPSY; BREAST CANCER; CLINICAL ARTICLE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BIOPSY, FINE-NEEDLE; BREAST NEOPLASMS; CRYOPRESERVATION; EOSINE YELLOWISH-(YS); FEMALE; GENE AMPLIFICATION; GENES, ERBB-2; HISTOCYTOLOGICAL PREPARATION TECHNIQUES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; METHYLENE BLUE; REPRODUCIBILITY OF RESULTS; STAINING AND LABELING;

EID: 10844240000     PISSN: 09565507     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2303.2004.00210.x     Document Type: Article

References (13)

1. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
2. Bozzetti C, Personeni N, Nizzoli R et al. HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer 2003;99:310-5.
3. Nour S. Utility of cytologic specimens in the evaluation of prognostic and predictive factors of breast cancer: current issues and future directions. Diagn Cytopathol 2004;30; 158-65.
4. Abati A, Sanford J, Fetsch P, Marincola F, Wolman S. Fluorescence in situ hybridization (FISH): a user's guide to optimal preparation of cytologic specimens. Diagn Cytopathol 1995;13:486-92.
5. Cajulis R, Frias-Hidvegi D. Detection of numerical chromosomal abnormalities in malignant cells on body fluids by fluorescence cell nuclei with chromosome-specific probes. Diagn Cytopathol 1992;8:627-31.
6. Cajulis R, Frias-Hidvegi D, Yu G, Eggena S. Detection of numerical chromosomal abnormalities by fluorescence in situ hybridization of interphase cell nuclei with chromosome-specific probes on archival cytologic samples. Diagn Cytopathol 1996;14:178-81.
7. Moore J, Patel S, Sneige N. HER-2/neu gene amplification in breast imprint cytology analyzed by fluorescence in situ hybridization: direct comparision with companion tissue sections. Diagn Cytopathol 2000;23: 299-302.
8. Klijanienko J, Couturier J, Galut M et al. Detection and quantification by fluorescence in situ hybridization (FISH) and image analysis of HER-2/neu gene amplification in breast cancer fine-needle samples. Cancer Cytopathol 1999;87:312-8.
9. Franzèn F, Zajicek J. Aspiration biopsy in diagnosis of palpable lesions of breast: critical review of 3479 consecutive biopsies. Acta Radiologic 1968;7:241-62.
10. Michael B, Mitch D, Wedad H et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003;16:173-82.
11. Varshney D, Zhou YY, Geller SA, Alsabeh R. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing Hercep Test and Path Vysion FISH Assay. Am J Clin Pathol 2004;121:70-7.
12. Watters AD, Going JJ, Cooke TG, Bartlett JMS. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat 2003;77:109-14.
13. Lal P, Salazar PA, Ladanyi M, Chen B. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn 2003;5:155-9.